Help Your Eligible Patients Save on ZIRGAN*
With the Bausch + Lomb Access Program, most eligible patients can save on their ZIRGAN prescriptions.*
Eligible* commercially insured patients may pay as little as $25. Eligible* uninsured patients or not covered patients may pay as little as $60.
Patients can download and activate a Bausch + Lomb Access card by visiting bauschaccessprogram.com.
- Patients who receive a physical co-pay card in office can activate online at blsavings.com, on the phone by calling
1-866-693-4880, or by texting BLSAVINGS to 24109† - Once the card has been downloaded or activated, patients can take it to Walgreens or a participating independent pharmacy to pick up their prescription
*Terms, conditions and limitations apply. See eligibility criteria and terms and conditions at bauschaccessprogram.com.
†Message and data rates may apply. Full terms can be viewed at https://bauschaccess.copaysavingsprogram.com/sms-terms.
Accessing ZIRGAN
See if your patients are covered with Bausch + Lomb’s formulary tool.
Check our formulary toolInterested in ZIRGAN samples?
Requesting samples is quick and easy through the Bausch Sample Vault.
Request samplesIndication
ZIRGAN® (ganciclovir ophthalmic gel) 0.15% is a topical ophthalmic antiviral that is indicated for the treatment of acute herpetic keratitis (dendritic ulcers).
Important Safety Information
- ZIRGAN is indicated for topical ophthalmic use only.
- Patients should not wear contact lenses if they have signs or symptoms of herpetic keratitis or during the course of therapy with ZIRGAN.
- Most common adverse reactions reported in patients were blurred vision (60%), eye irritation (20%), punctate keratitis (5%), and conjunctival hyperemia (5%).
- Safety and efficacy in pediatric patients below the age of 2 years have not been established.
Click here for full Prescribing Information for ZIRGAN.
ZIRGAN is a trademark of Laboratoires Théa Corporation used under license.
Indication
ZIRGAN® (ganciclovir ophthalmic gel) 0.15% is a topical ophthalmic antiviral that is indicated for the treatment of acute herpetic keratitis (dendritic ulcers).
Important Safety Information
- ZIRGAN is indicated for topical ophthalmic use only.
- Patients should not wear contact lenses if they have signs or symptoms of herpetic keratitis or during the course of therapy with ZIRGAN.
- Most common adverse reactions reported in patients were blurred vision (60%), eye irritation (20%), punctate keratitis (5%), and conjunctival hyperemia (5%).
- Safety and efficacy in pediatric patients below the age of 2 years have not been established.
Click here for full Prescribing Information for ZIRGAN.
ZIRGAN is a trademark of Laboratoires Théa Corporation used under license.
THIS WEBSITE IS INTENDED FOR U.S.
HEALTHCARE PROFESSIONALS ONLY.
Please choose an option below: